Advertisement

Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin’s lymphoma

  • M. El Far
  • M. Fouda
  • R. Yahya
  • H. El Baz
Article

Abstract

Interleukin 10 (IL-10) and interleukin 6 (IL-6) are widely investigated in solid tumors as being important prognostic factors. IL-10 and IL-6 serum levels were measured by enzyme-linked immunosorbent assay from sera taken from 40 non-Hodgkin’s lymphoma (NHL) patients before and after treatment and from 20 healthy controls. The patients had been observed for at least 18 months or until death. IL-10 and IL-6 were significantly higher in NHL patients compared to controls. IL-6 was correlated with IL-10 (r=0.451) and with B symptoms (weight loss > 10% during the last 6 months, unexplained fever and night sweats) (r=0.447). IL-10 and IL-6 were significantly higher in non survival compared to survival group. High pretreatment IL-10 and IL-6 was associated with poor overall survival. These results show that IL-10 and IL-6 levels are elevated in NHL patients and seem to suggest that simultaneous elevation of IL-10 and IL-6 is a powerful negative prognostic parameter in NHL.

Key words

IL-10 IL-6 Non-Hodgkin’s lymphoma (NHL) 

Niveles séricos de IL-10 y de IL-6 como factores de pronóstico en el linfoma no Hodgkin

Resumen

En numerosos trabajos se investiga acerca de las interleuquinas 10 (IL-10) y 6 (IL-6) como importantes factores de pronóstico en los tumores sólidos. En el presente trabajo, se. determinan los niveles de IL-10 y IL-6, mediante técnicas de enzimoinmunoanálisis, en suero de 40 pacientes con linfoma no Hodgkin (NHL), antes y despues del tratamiento, y en 20 controles sanos. Los pacientes habían sido estudiados durante al menos 18 meses o hasta su muerte. Se observa que los niveles de las dos interleuquinas están significativamente aumentados en los pacientes con NHL respecto de los controles. El nivel sérico de IL-6 se correlaciona con el de IL-10 (r=0,451) y con los síntomas B (pérdida de peso mayor al 10% durante los últimos 6 meses, fiebre no explicable y sudor nocturno) (r=0,447). Los niveles de IL-10 y de IL-6 son significativamente mayores en los no sobrevivientes respecto de los pacientes sobrevivientes. En conjunto, estos resultados muestran que los niveles de IL-10 y de IL-6 están incrementados en los pacientes con linfoma no Hodgkin y parecen sugerir que la simultánea elevación de ambas interleuquinas representa un factor de pronóstico negativo en esa patología.

Palabras clave

IL-10 IL-6 Linfoma no Hodgkin 

References

  1. 1.
    Shipp, M. A., Harrington, D. P., Anderson, J. R.et al. (1993):N. Engl. J. Med.,14, 987.Google Scholar
  2. 2.
    Black, K., Garrett, I. R. and Mundy, G. R. (1991):Endocrinology,128, 2657–2659.CrossRefPubMedGoogle Scholar
  3. 3.
    Blay, J. Y., Burdin, N., Rousset, F., Lenoir, G., Biron, P., Philip, T., Banchereau, J. and Favort, M. C. (1993):Blood,82, 2169–2174.PubMedGoogle Scholar
  4. 4.
    Del Prete, G., De Carli, M., Almerigogna, F., Giudizi, M. G., Biagiotti, R. and Romagnani, S. (1993):J. Immunol.,150, 353–360.PubMedGoogle Scholar
  5. 5.
    De Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C. G. and de Vries, J. E. (1991):J. Exp. Med.,174, 1209–1220.CrossRefPubMedGoogle Scholar
  6. 6.
    Emilie, D., Coumbaras, J., Raphael, M., Devergne, O., Delecluse, H. J., Gisselbrecht, C., Michiels, J. F., Van Damme, J., Taga, T., Kishimoto, T., Crevon, M. C. and Galanaud, P. (1992):Blood,80, 498–504.PubMedGoogle Scholar
  7. 7.
    Fayad, L., Cabanillas, F., Talpaz, M., McLaughlin, P. and Kurzrock, R. (1998):Leuk. Lymphoma,30, 563–571.PubMedGoogle Scholar
  8. 8.
    Fujita, J., Takenawa, J., Kaneko, Y., Okumura, K. and Yoshida, O. (1992):Acta. Urol. Jpn.,38, 1333–1336.Google Scholar
  9. 9.
    Gazzinelli, R. T., Makino, M., Chattopadhyay, S. K., Snapper, C. M., Sher, A., Hugin, A. W. and Morse, H. C. (1992):J. Immunol.,148, 182.PubMedGoogle Scholar
  10. 10.
    Gumerlock, P. H. and Li, J. H. (1993):Cancer Res.,34, A2950.Google Scholar
  11. 11.
    Howard, M. and O’Garra, A. (1992):Immunol. Today,13, 198–200.CrossRefPubMedGoogle Scholar
  12. 12.
    Jucker, M., Abts, H., Li, W., Schindler, R., Merz, H., Gunther, A., von Kalle, C., Schaadt, M., Diamantstein, T., Feller, A. C., Krueger, G. R. F., Diehl, V., Blankenstein, T. and Tesch, H. (1991):Blood,77, 2413–2418.PubMedGoogle Scholar
  13. 13.
    Lu, C. and Kerbel, R. S. (1993):J. Cell Biol.,120, 1281–1288.CrossRefPubMedGoogle Scholar
  14. 14.
    Masood, R., Bond, M., Scadden, D., Kaplan, M., Levine, A. M. and Gill, P. S. (1992):Blood,80: 115.Google Scholar
  15. 15.
    Miyazaki, I., Cheung, R. K. and Dosch, H. M. (1993):J. Exp. Med.,178, 439–447.CrossRefPubMedGoogle Scholar
  16. 16.
    Moore, D. F. and Cabanillas, F. (1998):Oncology,12: 17–24.PubMedGoogle Scholar
  17. 17.
    Moore, K. W., Malefyt, R. W., Coffman, R. L. and O’Garra, A. (2001):Annu. Rev. Immunol.,19, 683–765.CrossRefPubMedGoogle Scholar
  18. 18.
    Pagnano, K. B., Vassallo, J. and Lorand-Metzc, I. (2001):Am. J. Hemat.,67, 84–92.CrossRefPubMedGoogle Scholar
  19. 19.
    Preti, H. A., Cabanillas, F., Talpaz, M., Tucker, S. L., Seymour, J. F. and Kurzrock, R. (1997):Ann. Intern. Med.,127, 186–194.PubMedGoogle Scholar
  20. 20.
    Seymour, J. F., Talpaz, M., Cabanillas, F., Wetzler, M. and Karzrock, R. (1995):J. Clin. Oncol.,13, 575–582.PubMedGoogle Scholar
  21. 21.
    Shimizu, S., Hirano, T., Yoshioka, R., Sugal, S., Matsuda, T., Taga, T., Kishimoto, T. and Konda, S. (1988):Blood,72, 1826–1828.PubMedGoogle Scholar
  22. 22.
    Simon, R., Durrleman, S., Hoppe, R. T., Bonadonna, G., Bloomfield, C. D., Rudders, R. A., Cheson, B. D. and Berard, C. W. (1988):Ann. Int. Med.,109, 939–945.PubMedGoogle Scholar
  23. 23.
    Skinnider, B. F. and Mak, T. W. (2002):Blood,99, 4283–4297.CrossRefPubMedGoogle Scholar
  24. 24.
    Tracet, K. J. and Cerami, A. (1990):Ann. N. Y. Acad. Sci.,587, 325–331.Google Scholar
  25. 25.
    Van Sinck, J. (1990):Annu. Rev. Immunol.,8, 253–278.CrossRefGoogle Scholar
  26. 26.
    Viviani, S., Notti, P., Bonfante, V., Verderio, P., Valagussa, P. and Bonadonna, G. (2000):Med. Oncol.,17, 59–63.CrossRefPubMedGoogle Scholar
  27. 27.
    Voorzanger, N., Touitou, R., Garcia, E., Delecluse, H. J., Rousset, F., Joab, I., Favort, M. C. and Blay, J. Y. (1996):Cancer Res.,56: 5499–5505.PubMedGoogle Scholar
  28. 28.
    Wu, M. S., Wu, C. Y., Chen, C. J., Lin, M. T., Shun, C. T. and Lin, J. T. (2003):Int. J. Cancer,104, 617–623.CrossRefPubMedGoogle Scholar
  29. 29.
    Yee, C., Biondi, A., Wang, X. H., Iscove, N. N., de Sousa, J., Aarden, L. A., Wong, G. G., Clark, S. C., Messner, H. A. and Minden, M. D. (1989):Blood,74, 798–804.PubMedGoogle Scholar

Copyright information

© Universidad de Navarra 2004

Authors and Affiliations

  1. 1.Biochemistry Div., Faculty of ScienceMansoura UniversityEgypt
  2. 2.Haematology Unit, Clinical Pathology Dept., Faculty of MedicineMansoura UniversityEgypt
  3. 3.Children Hospital, Faculty of MedicineMansoura UniversityEgypt

Personalised recommendations